Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jun 21, 2014; 20(23): 7169-7180
Published online Jun 21, 2014. doi: 10.3748/wjg.v20.i23.7169
Published online Jun 21, 2014. doi: 10.3748/wjg.v20.i23.7169
Treatment of chronic hepatitis B in clinical practice with entecavir or tenofovir
Ezequiel Ridruejo, Hepatology Section, Departament of Medicine, Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno “CEMIC”, Ciudad Autónoma de Buenos Aires, C1425ASG Buenos Aires, Argentina
Ezequiel Ridruejo, Hepatology and Liver Transplant Unit, Hospital Universitario Austral, Pilar, Provincia de Buenos Aires, C1425ASG Buenos Aires, Argentina
Author contributions: Ridruejo E analyzed all the data and wrote the paper.
Correspondence to: Ezequiel Ridruejo, MD, Hepatology Section, Department of Medicine, Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno “CEMIC”, Ciudad Autónoma de Buenos Aires, Avda, Las Heras 2939, C1425ASG Buenos Aires, Argentina. eridruejo@gmail.com
Telephone: +54-11-48091980 Fax: +54-11-48091992
Received: October 15, 2013
Revised: November 20, 2013
Accepted: January 2, 2014
Published online: June 21, 2014
Processing time: 248 Days and 18.6 Hours
Revised: November 20, 2013
Accepted: January 2, 2014
Published online: June 21, 2014
Processing time: 248 Days and 18.6 Hours
Core Tip
Core tip: Patients treated with entecavir or tenofovir in routine clinical practice at referral centres, with good clinical follow-up and adherence to international guidelines, can achieve high treatment response rates with a very low rate of adverse events.